We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivating progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
Naturally repairing or reversing damage caused by degenerative disease
Executive Chairman
Co-founder, President and CEO
Co-founder and CEO and Chairman of Sepracor (retired)
Institute Professor, Massachusetts Institute of Technology
Executive Chairman and Founder, Alexandria Real Estate
Managing Partner, Taiwania Capital Management
